Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Allergy and Immunology›Condition·Updated Jul 11, 2026·v1

Common Variable Immunodeficiency

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults, characterized by hypogammaglobulinemia, defective antibody responses, and recurrent sinopulmonary infections. Non-infectious complications including autoimmune cytopenias, lymphoproliferation, GLILD, and malignancy now dominate morbidity and mortality. Early immunoglobulin replacement reduces infections, but management of complications requires targeted immunosuppression and close surveillance.

Moderate Evidence235 references·2,788 words·12 min read·v1
Common Variable ImmunodeficiencyCVIDPrimary ImmunodeficiencyHypogammaglobulinemiaRecurrent InfectionsAutoimmune CytopeniasGLILDNFKB1CTLA4Immunoglobulin Replacement

Quick Reference

RxDrug of choiceImmunoglobulin replacement therapy (IVIG 400-600 mg/kg q3-4wk or SCIG 100-200 mg/kg weekly) titrated to individual trough.
AltAlternativesAntimicrobial prophylaxis (TMP-SMX DS daily or azithromycin 250 mg TIW); for non-infectious complications: prednisone ≥0.3 mg/kg/day, rituximab 150-375 mg/m², abatacept (CTLA-4 insufficiency), sirolimus (LRBA deficiency), omalizumab (CSU), PD-1 inhibitors (malignancy).
⊘AvoidLive vaccines; IgA-containing IVIG in patients with anti-IgA antibodies; non-dihydropyridine CCBs (diltiazem, verapamil) in CVID with cardiac involvement.
DxTest of choiceSerum immunoglobulins (IgG, IgA, IgM, IgE) plus vaccine response testing (pneumococcal polysaccharide + protein antigens) plus B-cell immunophenotyping (switched memory B cells, CD21low B cells).
ScKey scoreEUROclass classification (smB <2% = high risk; CD21low >10% = lymphoproliferation) and clinical phenotype (infection-only vs complicated CVID).
→When to referRefer to immunology at diagnosis; consider specialized center for complicated CVID (non-infectious complications, monogenic defect, refractory disease, need for HSCT or targeted biologic).
CVID is the most common primary immunodeficiency in adults, driven by humoral and T-cell defects. Early immunoglobulin replacement reduces infections, but non-infectious complications (autoimmune cytopenias, lymphoproliferation, GLILD, malignancy) determine prognosis and require targeted immunosuppression. Monogenic causes guide therapy, and systematic surveillance improves outcomes.
Common Variable Immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults, defined by low immunoglobulins and impaired antibody responses, leading to recurrent infections, autoimmunity, and malignancy. This concise reference covers pathophysiology, diagnosis, management, and prognosis for bedside use.

Overview and Recommendations

Background

  • •CVID is the most common symptomatic primary immunodeficiency in adults, with an estimated prevalence of 1 in 500 to 1 in 500,000. It is defined by low serum IgG and low IgA (with or without low IgM) and defective specific antibody production, leading to recurrent infections and immune dysregulation that spans B- and T-cell compartments.
  • •The classic presentation involves recurrent sinopulmonary infections (pneumonia as first manifestation in 32% of patients), but non-infectious complications, autoimmune cytopenias (ITP, AIHA, Evans syndrome), lymphoproliferation (splenomegaly, lymphadenopathy), enteropathy, granulomatous-lymphocytic interstitial lung disease (GLILD), and malignancy, now drive most morbidity. The presence of even one non-infectious complication confers an 11-fold increase in mortality compared with infection-only disease.
  • •Pathophysiology centers on a fundamental B-cell maturational defect (reduced class-switched memory B cells) compounded by T-cell dysregulation: follicular helper T-cell expansion, regulatory T-cell deficiency, and chronic innate immune activation driven by microbial translocation. IgA deficiency with impaired anti-LPS antibodies permits endotoxemia, which triggers a BTK-dependent proinflammatory cytokine cascade (TNF-α, IL-6, IFN-γ, CXCL9, CXCL10) in genetically susceptible individuals.
  • •Monogenic causes are identified in 20-30% of patients, most commonly heterozygous loss-of-function variants in (4% of Europeans), haploinsufficiency, deficiency, and defects in , , , and . Identification of a specific genetic defect can guide targeted therapy (e.g., abatacept for CTLA-4 insufficiency, sirolimus for LRBA deficiency) and consideration of hematopoietic stem cell transplantation.
  • •Diagnostic criteria per ESID/ICON require onset after age 2 years, low IgG and low IgA (and/or low IgM), impaired vaccine responses to pneumococcal polysaccharide and protein antigens, and exclusion of secondary causes of hypogammaglobulinemia. Patients are clinically stratified into infection-only (CVIDio) and complicated CVID (CVIDc), the latter encompassing autoimmune, lymphoproliferative, enteropathic, and malignant phenotypes, to guide prognosis and surveillance intensity.

Evaluation

  • •Suspect CVID in any adult with recurrent sinopulmonary infections (≥2 pneumonias in 1 year, chronic sinusitis, otitis media), especially when accompanied by unexplained autoimmune cytopenia, splenomegaly, lymphadenopathy, chronic diarrhea, or bronchiectasis.
  • •Ask about age at first serious infection, frequency of antibiotic courses, history of pneumonia, bronchiectasis, autoimmune disease (ITP, AIHA, Evans syndrome), family history of immunodeficiency, and prior immunoglobulin measurements. Diagnostic delay averages 5-8 years, so maintain a low threshold.
  • •Examine for signs of chronic lung disease (crackles, clubbing), lymphadenopathy, splenomegaly, mucocutaneous candidiasis, and skin findings (vitiligo in 8.5%, eczema in 22.4%, purpura from thrombocytopenia).
  • •Order initial laboratory workup: complete blood count with differential, serum immunoglobulins (IgG, IgA, IgM, IgE), and serum protein electrophoresis with calculated globulin (CG <22 g/L has 80% sensitivity, 87% specificity for hypogammaglobulinemia). Low IgG and low IgA are required for diagnosis.
  • •Evaluate specific antibody responses by measuring pre- and 4-week post-vaccination titers to pneumococcal polysaccharide (Pneumovax) and protein antigens (tetanus, diphtheria). Failure to achieve a ≥2-fold rise or protective levels in <70% of serotypes defines the defect. If the patient is already on IVIG, use ELISPOT assay for antibody-secreting cells instead of serology.
  • •Perform B-cell immunophenotyping by flow cytometry: quantify switched memory B cells (CD27+IgD-), marked reduction (<2% of B cells) is a hallmark of CVID and predicts non-infectious complications. Expansion of CD21low B cells (>5% of B cells) correlates with GLILD and splenomegaly.
  • •Assess T-cell subsets: low naive CD4+ T cells (<20% of total CD4+) defines late-onset combined immunodeficiency (LOCID), which independently predicts splenomegaly, lymphadenopathy, interstitial lung disease, lymphoma, and shortened survival.
  • •Consider serum B-cell maturation antigen (sBCMA) as a novel biomarker: <15 ng/mL has 97% positive predictive value for CVID or X-linked agammaglobulinemia; ≥25 ng/mL has 88% negative predictive value.
  • •Genetic testing (targeted gene panel or whole exome) is indicated for patients with non-infectious complications dominating the phenotype, family history of immunodeficiency, or severe/atypical infections. Identification of a monogenic cause (NFKB1, CTLA4, LRBA, etc.) can direct targeted therapy and cascade screening of relatives.
  • •In patients with atopic symptoms but negative skin prick testing or serum specific IgE, consider bronchial challenge to confirm allergic asthma, as standard allergy testing is often falsely negative in CVID (only 9.7% have atopy by skin test despite suggestive histories).
  • •Rule out secondary causes of hypogammaglobulinemia: medications (rituximab, anticonvulsants, sulfasalazine), protein-losing enteropathy, nephrotic syndrome, lymphoproliferative diseases (CLL, thymoma/Good syndrome), and chronic infections (HIV, EBV, CMV).
  • •Perform baseline screening for established complications: high-resolution chest CT (HRCT) to assess for bronchiectasis and GLILD, pulmonary function tests including FVC and DLCO, and upper endoscopy with standardized biopsies to screen for atrophic gastritis and intestinal metaplasia (found in 34% of CVID patients) if gastrointestinal symptoms are present.
  • •Refer to an immunologist for confirmation and initiation of immunoglobulin replacement therapy; coordinate a multidisciplinary approach including pulmonology, gastroenterology, and hematology for complicated cases.

Management

  • •Initiate immunoglobulin replacement therapy (IgRT) as soon as the diagnosis is confirmed. Start 400-600 mg/kg every 3-4 weeks or 100-200 mg/kg weekly; titrate the dose to maintain a trough IgG >700-800 mg/dL, though the ideal level should be individualized based on breakthrough infection frequency.
  • •SCIG is increasingly preferred for its flexibility, fewer systemic adverse effects, suitability for home administration, and improved quality of life. IVIG remains appropriate for patients who prefer center-based therapy or have adherence concerns.
  • •For breakthrough sinopulmonary infections despite adequate trough IgG levels, add antimicrobial prophylaxis: one double-strength tablet daily or 250 mg three times weekly. Tailor choice based on sputum culture results when possible.
  • •Manage GLILD with high-dose corticosteroids: initiate at ≥0.3 mg/kg daily (or equivalent). This regimen improves HRCT scores and forced vital capacity, achieving durable remission in approximately 42% of patients. Low-dose maintenance (<0.3 mg/kg) provides no added benefit, taper to the lowest effective dose over 4-8 weeks.
  • •For steroid-refractory or relapsing GLILD, use -based therapy. Low-dose rituximab 150 mg/m² weekly may achieve remission with fewer infections; standard-dose rituximab 375 mg/m² every 3 weeks is an alternative but carries a higher risk of opportunistic infections. Combination with azathioprine (dose per protocol) has shown benefit in case series.
  • •For autoimmune cytopenias (ITP, AIHA, Evans syndrome), first-line treatment is high-dose corticosteroids (e.g., pulse therapy). For refractory cases, consider rituximab, azathioprine, or other steroid-sparing immunosuppressants. Maintain IgG trough >7 g/L to reduce autoimmune thrombocytopenia episodes.
  • •In monogenic CVID due to haploinsufficiency, administer abatacept (CTLA-4 fusion protein) as targeted therapy. Hematopoietic stem cell transplantation (HSCT) can achieve sustained remission in 72% of CTLA-4 mutation carriers and is also an option for severe deficiency or other monogenic defects with refractory immune dysregulation.
  • •For LRBA deficiency, (mTOR inhibitor) has demonstrated efficacy in reducing lymphoproliferation and autoimmunity; consider HSCT if disease is severe and progressive.
  • •For refractory chronic spontaneous urticaria in CVID, can induce complete remission after the first injection and is well tolerated over 12 months.
  • •For malignancy arising in CVID (e.g., lung adenocarcinoma, lymphoma), (nivolumab, pembrolizumab) have been used successfully, achieving partial response with progression-free survival >15 months. Do not automatically exclude CVID patients from checkpoint inhibitor trials.
  • •Vaccination: administer inactivated influenza vaccine annually and mRNA vaccine series with boosters as recommended. Humoral responses develop in 52-83% of CVID patients but wane rapidly; T-cell responses are more durable and correlate with protection against severe disease. Live vaccines are contraindicated.
  • •Monitor for complications systematically: perform annual pulmonary function tests; repeat HRCT every 1-2 years if GLILD is present (consider MRI as radiation-sparing alternative); screen for gastric cancer with baseline upper endoscopy and standardized biopsies at diagnosis, then every 3-5 years (especially in smokers or with H. pylori infection).
  • •Intubation criteria for acute respiratory failure: FVC <20 mL/kg ideal body weight, PaO2/FiO2 ratio <150 mm Hg on non-rebreather, hypercapnia (PaCO2 >50 mm Hg with pH <7.30), or signs of impending fatigue (accessory muscle use, respiratory rate >35 breaths/min, abdominal paradox).
  • •Provide standard VTE prophylaxis for hospitalized CVID patients: 40 mg SC daily or 5000 U SC twice daily, unless bleeding risk from severe thrombocytopenia or active bleeding.
  • •Refer patients with complicated CVID (non-infectious complications, monogenic defect, refractory disease) to specialized immunology/transplant centers for consideration of targeted biologic therapies or HSCT.
  • •In pregnancy, continue IgRT to maintain trough IgG >500-700 mg/dL; IVIG is safe with no moderate/severe adverse effects. Coordinate multidisciplinary care with maternal-fetal medicine, immunology, and neonatology. Breastfeeding is encouraged as colostrum contains protective antibodies against enteropathogenic E. coli.
  • •In elderly patients, individualize IgG trough targets to balance infection prevention against volume overload; SCIG may be preferred to avoid hemodynamic stress of IVIG. Monitor for comorbidities (chronic lung disease, diabetes, hypertension) that complicate management.
  • •Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they exacerbate heart failure in patients with cardiac involvement. Avoid IgA-containing immunoglobulin products in patients with known anti-IgA antibodies at risk of anaphylaxis.
  • •Monitor for iatrogenic complications: corticosteroids increase opportunistic infection risk (2 cases in one series); rituximab may worsen humoral deficiency (compensated by IgRT); checkpoint inhibitors can trigger immune-related adverse events. Adjust immunosuppression in collaboration with the primary immunologist.

Board Review — High Yield

  • •Low IgG + IgA + impaired vaccine responses, Diagnostic triad for CVID; require onset after age 2 and exclusion of secondary causes.
  • •EUROclass smB- group, Switched memory B cells <2% of total B cells predicts splenomegaly, granulomatous disease, and lymphoma.
  • •CVIDc (complicated CVID), Presence of any non-infectious complication (cytopenias, lymphoproliferation, enteropathy) increases mortality 11-fold.
  • •NFKB1 haploinsufficiency, Most common monogenic cause (4% of Europeans); causes progressive B-cell defect, autoimmunity, and bronchiectasis.
  • •GLILD, Granulomatous-lymphocytic interstitial lung disease; diagnosed by HRCT + biopsy; treated with high-dose corticosteroids (≥0.3 mg/kg prednisone) ± rituximab.
  • •IVIG vs SCIG, Both first-line; SCIG has fewer systemic reactions and enables home therapy; target trough IgG >700-800 mg/dL.
  • •CTLA-4 insufficiency, Responds to abatacept; HSCT can be curative.
  • •Vaccination in CVID, Humoral responses blunted (52-83% seroconversion to COVID-19 mRNA vaccine, rapid waning); T-cell responses more durable; live vaccines contraindicated.
  • •Diagnostic delay, Averages 5-8 years; maintain high index of suspicion in adults with recurrent infections + autoimmunity or lymphoproliferation.
  • •Anaphylaxis risk, FCGR2A gain-of-function variant predisposes to IVIG reactions; switch to SCIG or use IgA-depleted products.

Deep Dive — Evidence Details

References

  1. [1]

    Unger S, Seidl M, van Schouwenburg P et al.. “The TH1 phenotype of follicular helper T cells indicates an IFN-γ-associated immune dysregulation in patients with CD21low common variable immunodeficiency.” The Journal of allergy and clinical immunology (2017). PMID: 28554560 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Hypersensitivity Mechanism Type
  2. [2]

    Jamee M, Zaki-Dizaji M, Lo B et al.. “Clinical, Immunological, and Genetic Features in Patients with Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndrome.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32428713 ↗

    L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Prognosis & Natural History
  3. [3]

    DiGiacomo DV, Roelstraete B, Lebwohl B et al.. “Predominantly antibody deficiency and the association with celiac disease in Sweden: A nationwide case-control study.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 38331244 ↗

    L3CASE_CONTROLCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors
  4. [4]

    Kaplan B, Kopyltsova Y, Khokhar A et al.. “Rituximab and immune deficiency: case series and review of the literature.” The journal of allergy and clinical immunology. In practice (2014). PMID: 25213054 ↗

    L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  5. [5]

    Fedor ME, Rubinstein A. “Effects of long-term low-dose corticosteroid therapy on humoral immunity.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 16892792 ↗

    L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway
  6. [6]

    Schwab C, Gabrysch A, Olbrich P et al.. “Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.” The Journal of allergy and clinical immunology (2018). PMID: 29729943 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks
  7. [7]

    Magerus A, Rensing-Ehl A, Rao VK et al.. “Autoimmune lymphoproliferative immunodeficiencies (ALPIDs): A proposed approach to redefining ALPS and other lymphoproliferative immune disorders.” The Journal of allergy and clinical immunology (2023). PMID: 37977527 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  8. [8]

    Lorenzini T, Fliegauf M, Klammer N et al.. “Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.” The Journal of allergy and clinical immunology (2020). PMID: 32278790 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  9. [9]

    Jørgensen SF, Braadland PR, Ueland T et al.. “Tryptophan-kynurenine metabolites associate with inflammation and immunologic phenotypes in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 40378971 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks
  10. [10]

    Chinen J, Notarangelo LD, Shearer WT. “Advances in basic and clinical immunology in 2014.” The Journal of allergy and clinical immunology (2015). PMID: 25956014 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History, Prevention, Screening & Surveillance
  11. [11]

    Tuijnenburg P, Lango Allen H, Burns SO et al.. “Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.” The Journal of allergy and clinical immunology (2018). PMID: 29477724 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  12. [12]

    Friedmann D, Payne KJ, Cousin V et al.. “Expansion of a distinct cytotoxic CD4 TFH-cell cluster in lymph nodes of patients with complicated common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 41314478 ↗

    L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type
  13. [13]

    Agondi RC, Barros MT, Rizzo LV et al.. “Allergic asthma in patients with common variable immunodeficiency.” Allergy (2009). PMID: 19839975 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  14. [14]

    DiGiacomo DV, Roelstraete B, Hammarström L et al.. “Predominant Antibody Deficiency and Risk of Microscopic Colitis: a Nationwide Case-Control Study in Sweden.” Journal of clinical immunology (2023). PMID: 37162615 ↗

    L3CASE_CONTROLCited in: Definition, Classification & Hypersensitivity Mechanism Type
  15. [15]

    Seidel MG, Kindle G, Gathmann B et al.. “The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.” The journal of allergy and clinical immunology. In practice (2019). PMID: 30776527 ↗

    L5OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  16. [16]

    Bez P, Smits B, Geier C et al.. “Uncovering Risk Factors of Premature Mortality in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40090481 ↗

    L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  17. [17]

    Ameratunga R, Edwards ESJ, Lehnert K et al.. “The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like Disorders.” The journal of allergy and clinical immunology. In practice (2023). PMID: 36796510 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  18. [18]

    Filion CA, Taylor-Black S, Maglione PJ et al.. “Differentiation of Common Variable Immunodeficiency From IgG Deficiency.” The journal of allergy and clinical immunology. In practice (2018). PMID: 30557717 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks
  19. [19]

    Elmoursi A, DiGiacomo DV, Farmer JR et al.. “Hepatic Manifestations in Common Variable Immunodeficiency Associated With Mortality and Worse Hospital Outcomes in Nationwide Analysis Using National Readmission Database.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40998257 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks
  20. [20]

    Agress A, Oprea Y, Roy S et al.. “The Association Between Malignancy, Immunodeficiency, and Atopy in IgE-Deficient Patients.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37863316 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors
  21. [21]

    Ogershok PR, Hogan MB, Welch JE et al.. “Spectrum of illness in pediatric common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 17165275 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Special Populations & Pregnancy
  22. [22]

    Ariue B, Patel NC, Bellanti JA. “Lessons from the American College of Allergy, Asthma and Immunology inborn errors of immunity survey: Advancing diagnostic and therapeutic strategies for the practicing allergist-immunologist.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41057108 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  23. [23]

    Lee WI, Huang JL, Kuo ML et al.. “Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 18051214 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type
  24. [24]

    Ombrello MJ, Remmers EF, Sun G et al.. “Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.” The New England journal of medicine (2012). PMID: 22236196 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  25. [25]

    Park MA, Li JT, Hagan JB et al.. “Common variable immunodeficiency: a new look at an old disease.” Lancet (London, England) (2008). PMID: 18692715 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  26. [26]

    Urban B, Batlle-Masó L, Perurena-Prieto J et al.. “Heterozygous Predicted Loss-of-function Variants of TRAF3 in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2024). PMID: 39579173 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  27. [27]

    Drabe CH, Laustsen MM, Marquart HV et al.. “Genetics in a Danish Common Variable Immunodeficiency Cohort.” Journal of clinical immunology (2025). PMID: 40455168 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  28. [28]

    Thoré P, Jaïs X, Savale L et al.. “Pulmonary Hypertension in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2021). PMID: 34110542 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  29. [29]

    Bargir UA, Setia P, Desai M et al.. “Common Variable Immunodeficiency Disorder: A Decade of Insights from a Cohort of 150 Patients in India and the Use of Machine Learning Algorithms to Predict Severity.” Journal of clinical immunology (2025). PMID: 40856873 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy
  30. [30]

    Thouvenel CD, Tipton CM, Yamazaki Y et al.. “Hypomorphic RAG2 Deficiency Promotes Selection of Self-Reactive B Cells.” Journal of clinical immunology (2025). PMID: 39812873 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  31. [31]

    van Stigt AC, von der Thüsen JH, Mustafa DAM et al.. “Granulomas in Common Variable Immunodeficiency Display Different Histopathological Features Compared to Other Granulomatous Diseases.” Journal of clinical immunology (2024). PMID: 39373788 ↗

    L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  32. [32]

    Fortier JC, Haltigan E, Cavero-Chavez V et al.. “Clinical and Phenotypic Characterization of Common Variable Immunodeficiency Diagnosed in Younger and Older Adults.” Journal of clinical immunology (2022). PMID: 35588029 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
  33. [33]

    Hägele P, Staus P, Scheible R et al.. “Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study.” The Lancet. Haematology (2024). PMID: 38302222 ↗

    L2COHORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification
  34. [34]

    Llobet MP, Soler-Palacin P, Detkova D et al.. “Common variable immunodeficiency: 20-yr experience at a single centre.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2008). PMID: 18798799 ↗

    L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Prevention, Screening & Surveillance
  35. [35]

    Perez-Perez D, Santos-Argumedo L, Rodriguez-Alba JC et al.. “Analysis of LRBA pathogenic variants and the association with functional protein domains and clinical presentation.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 38923448 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
  36. [36]

    Costagliola G, De Marco E, Amato L et al.. “Sponge-like sonographic pattern of the spleen in immune dysregulation disorders.” Frontiers in immunology (2026). PMID: 42375368 ↗

    L3CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  37. [37]

    Endo Y, Koga T, Kurushima S et al.. “Case Report: Novel IRF2BP2 variant in a Japanese patient with impaired B-cell differentiation, Th1 polarization, and systemic immune dysregulation.” Frontiers in immunology (2025). PMID: 41246352 ↗

    L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation
  38. [38]

    Sormani J, Belot A, Nove-Josserand R et al.. “A New Variant in CTLA4 Highlights the Heterogeneous Phenotype of CTLA4 Haploinsufficiency.” Journal of clinical immunology (2025). PMID: 41219619 ↗

    L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  39. [39]

    Nishikawa T, Tomomasa D, Hijikata A et al.. “Case Report: CD40LG Arg203Ile variant underlies atypical phenotype of X-linked hyper IgM syndrome.” Frontiers in immunology (2025). PMID: 40391217 ↗

    L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  40. [40]

    González-Torbay A, Reche-Yebra K, Clemente-Bernal Á et al.. “Functional insights of an uncommon hypomorphic variant in IL2RG as a monogenic cause of CVID-like disease with antibody deficiency and T CD4 lymphopenia.” Frontiers in immunology (2025). PMID: 40170851 ↗

    L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism
  41. [41]

    Ak B, Parıltay E, Gümüşburun R et al.. “Uniparental Disomy of Chromosome 4: A Case of Whole Chromosome UPD Presenting with LRBA Deficiency.” Journal of clinical immunology (2024). PMID: 39289195 ↗

    L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism
  42. [42]

    Le Coz C, Bengsch B, Khanna C et al.. “Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage.” The Journal of allergy and clinical immunology (2019). PMID: 31445098 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  43. [43]

    von Spee-Mayer C, Echternach C, Agarwal P et al.. “Abatacept Use Is Associated with Steroid Dose Reduction and Improvement in Fatigue and CD4-Dysregulation in CVID Patients with Interstitial Lung Disease.” The journal of allergy and clinical immunology. In practice (2020). PMID: 33223097 ↗

    L2TRIAL_NONRANDOMCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway
  44. [44]

    Lang A, Agharahimi A, Vogel TP et al.. “From CVID to PIRD: Genetic Testing Leading to Signal Transducer and Activator of Transcription 3 Gain-of-Function Diagnosis and Directed Therapy.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41999916 ↗

    L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  45. [45]

    Agarwal S, Cunningham-Rundles C. “Thymoma and immunodeficiency (Good syndrome): a report of 2 unusual cases and review of the literature.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17304889 ↗

    L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  46. [46]

    Narula S, LaRosa DF, Kamoun M et al.. “Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17521034 ↗

    L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation
  47. [47]

    Udemgba C, Pillay B, Shafer S et al.. “IRF2BP2 deficiency: An important form of common variable immunodeficiency with inflammation.” The Journal of allergy and clinical immunology (2025). PMID: 40090425 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  48. [48]

    Chinen J, Cowan MJ. “Advances and highlights in primary immunodeficiencies in 2017.” The Journal of allergy and clinical immunology (2018). PMID: 30170128 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  49. [49]

    Abyazi ML, Bell KA, Gyimesi G et al.. “Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications.” The Journal of allergy and clinical immunology (2021). PMID: 34146579 ↗

    L3OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
  50. [50]

    Kaarbø M, Yang M, Hov JR et al.. “Duodenal inflammation in common variable immunodeficiency has altered transcriptional response to viruses.” The Journal of allergy and clinical immunology (2022). PMID: 36220400 ↗

    L3OTHERCited in: Pathophysiology & Immune Mechanism
  51. [51]

    Le Coz C, Trofa M, Butler DL et al.. “The common variable immunodeficiency IgM repertoire narrowly recognizes erythrocyte and platelet glycans.” The Journal of allergy and clinical immunology (2024). PMID: 38692308 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism
  52. [52]

    Ho HE, Radigan L, Qi J et al.. “Bruton tyrosine kinase modulates systemic immune activation to bacterial translocation in primary antibody deficiencies.” The Journal of allergy and clinical immunology (2025). PMID: 41033468 ↗

    L2OTHERCited in: Pathophysiology & Immune Mechanism
  53. [53]

    Boast B, Goel S, González-Granado LI et al.. “TCF3 haploinsufficiency defined by immune, clinical, gene-dosage, and murine studies.” The Journal of allergy and clinical immunology (2023). PMID: 37277074 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  54. [54]

    Urdea D, Mereuta DV, Iorga RE et al.. “Concurrent hereditary angioedema type I and common variable immunodeficiency presenting as suspected antibiotic hypersensitivity: Case report and literature discussion.” The World Allergy Organization journal (2026). PMID: 42221876 ↗

    L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  55. [55]

    Friedmann D, Goldacker S, Peter HH et al.. “Preserved Cellular Immunity Upon Influenza Vaccination in Most Patients with Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32330665 ↗

    L2OTHERCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
  56. [56]

    Schussler E, Beasley MB, Maglione PJ. “Lung Disease in Primary Antibody Deficiencies.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27836055 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
  57. [57]

    Yin J, Hayes KM, Ong MS et al.. “Common Variable Immunodeficiency Clinical Manifestations Are Shaped by Presence and Type of Heterozygous NFKB1 Variants.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39672378 ↗

    L2OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
  58. [58]

    Ameratunga R, Longhurst H, Steele R et al.. “Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19.” The journal of allergy and clinical immunology. In practice (2021). PMID: 34182162 ↗

    L5OTHERCited in: Pathophysiology & Immune Mechanism, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
  59. [59]

    Milota T, Smetanova J, Skotnicova A et al.. “Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36379409 ↗

    L2OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
  60. [60]

    van de Ven A, Mader I, Wolff D et al.. “Structural Noninfectious Manifestations of the Central Nervous System in Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31857261 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism
  61. [61]

    Agarwal S, Cunningham-Rundles C. “Autoimmunity in common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2019). PMID: 31349011 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  62. [62]

    Durkee-Shock JR, Keller MD. “Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2022). PMID: 35718282 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prevention, Screening & Surveillance
  63. [63]

    Ballow M. “Managing comorbid complications in patients with common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2013). PMID: 24267402 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Complications, Comorbidities & Iatrogenic Risks
  64. [64]

    Maglione PJ, Overbey JR, Radigan L et al.. “Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2014). PMID: 24880814 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  65. [65]

    Rosenthal JA, Papa MP, Sanz M et al.. “Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2023). PMID: 36736722 ↗

    L2OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
  66. [66]

    Hashiguchi S, Tomomasa D, Nishikawa T et al.. “18q Deletion Syndrome Presenting with Late-Onset Combined Immunodeficiency.” Journal of clinical immunology (2024). PMID: 38896123 ↗

    L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism
  67. [67]

    Vossen MG, Kartnig F, Mrak D et al.. “Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency : A prospective controlled open-label trial.” Wiener klinische Wochenschrift (2024). PMID: 39446203 ↗

    L2RCTCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway
  68. [68]

    Yel L. “Selective IgA deficiency.” Journal of clinical immunology (2010). PMID: 20101521 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway
  69. [69]

    Cunningham-Rundles C. “Autoimmune manifestations in common variable immunodeficiency.” Journal of clinical immunology (2008). PMID: 18322785 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
  70. [70]

    Strohmeier V, Andrieux G, Unger S et al.. “Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection.” Journal of clinical immunology (2022). PMID: 36282455 ↗

    L2OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
  71. [71]

    Sekinaka Y, Mitsuiki N, Imai K et al.. “Common Variable Immunodeficiency Caused by FANC Mutations.” Journal of clinical immunology (2017). PMID: 28493158 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  72. [72]

    Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R et al.. “Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.” Journal of clinical immunology (2021). PMID: 34787773 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
  73. [73]

    Rodríguez-Cortez VC, Del Pino-Molina L, Rodríguez-Ubreva J et al.. “Dissecting Epigenetic Dysregulation of Primary Antibody Deficiencies.” Journal of clinical immunology (2016). PMID: 26984849 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
  74. [74]

    Hel Z, Huijbregts RP, Xu J et al.. “Altered serum cytokine signature in common variable immunodeficiency.” Journal of clinical immunology (2014). PMID: 25246148 ↗

    L3OTHERCited in: Pathophysiology & Immune Mechanism
  75. [75]

    Yang M, Kaarbø M, Myhre V et al.. “Altered Genome-Wide DNA Methylation in the Duodenum of Common Variable Immunodeficiency Patients.” Journal of clinical immunology (2024). PMID: 38780872 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism
  76. [76]

    Soltani M, Rezaei M, Fekrvand S et al.. “Role of rare immune cells in common variable immunodeficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 34937129 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  77. [77]

    Yong PL, Orange JS, Sullivan KE. “Pediatric common variable immunodeficiency: immunologic and phenotypic associations with switched memory B cells.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2010). PMID: 20337966 ↗

    L2OTHERCited in: Pathophysiology & Immune Mechanism, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  78. [78]

    Lenti MV, Savioli J, Achilli G et al.. “Autoimmune diseases associated with common variable immune deficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 33236426 ↗

    L5OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks
  79. [79]

    Kutukculer N, Gulez N. “The outcome of patients with unclassified hypogammaglobulinemia in early childhood.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19196447 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  80. [80]

    Tegtmeyer D, Seidl M, Gerner P et al.. “Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2017). PMID: 28513998 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  81. [81]

    Zeng W, Feng X, Liang B et al.. “Good syndrome presenting with multiple pulmonary infections: a case report involving metagenomic sequencing diagnosis.” Frontiers in medicine (2025). PMID: 40904363 ↗

    L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
  82. [82]

    Consolini R, Maestrini G, Abu-Rumeileh S et al.. “The Intertwining Between Arthritis and Inborn Errors of Immunity.” Journal of clinical medicine (2026). PMID: 42123030 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
  83. [83]

    Yang M, Kaarbø M, Myhre V et al.. “Distinct Proteomic and Transcriptomic Profiles in T-cells and Monocytes in Patients with Common Variable Immunodeficiency: an Exploratory Study.” Journal of clinical immunology (2026). PMID: 41991796 ↗

    L3OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
  84. [84]

    Comans SET, Sprenkeler EGG, Koenen MH et al.. “Familial patterns of immune dysregulation in CVID: insights from B- and T-cell phenotyping and antibody profiling.” Frontiers in immunology (2026). PMID: 41909677 ↗

    L4OTHERCited in: Pathophysiology & Immune Mechanism, Prevention, Screening & Surveillance
  85. [85]

    Briassouli E, Marinakis N, Spoulou V et al.. “IL2RG-related immunodeficiencies: from SCID to atypical presentations.” Frontiers in immunology (2026). PMID: 41909668 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Prognosis & Natural History
  86. [86]

    Fekrvand S, Abolhassani H, Esfahani ZH et al.. “Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.” Journal of clinical immunology (2024). PMID: 39466473 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
  87. [87]

    Egg D, Rump IC, Mitsuiki N et al.. “Therapeutic options for CTLA-4 insufficiency.” The Journal of allergy and clinical immunology (2021). PMID: 34111452 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
  88. [88]

    Torres-Valle A, Neirinck J, Silva SL et al.. “Immunologic biomarkers of noninfectious complications and overall survival in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 41176068 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  89. [89]

    Gray PE, David C. “Inborn Errors of Immunity and Autoimmune Disease.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37119983 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
  90. [90]

    Jolles S. “The variable in common variable immunodeficiency: a disease of complex phenotypes.” The journal of allergy and clinical immunology. In practice (2013). PMID: 24565700 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks
  91. [91]

    Cunningham-Rundles C. “Current concepts: Common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41274495 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
  92. [92]

    Moazzami B, Mohayeji Nasrabadi MA, Abolhassani H et al.. “Comprehensive assessment of respiratory complications in patients with common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32007567 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  93. [93]

    Ferastraoaru D, Gross R, Rosenstreich D. “Increased malignancy incidence in IgE deficient patients not due to concomitant Common Variable Immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 28778662 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  94. [94]

    De Renzis C, Gambier RF, Gigante A et al.. “Chronic Kidney Disease in Common Variable Immunodeficiency: a Multicenter Study.” Journal of clinical immunology (2025). PMID: 40407942 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  95. [95]

    van der Poorten DK, McLeod D, Ahlenstiel G et al.. “Gastric Cancer Screening in Common Variable Immunodeficiency.” Journal of clinical immunology (2018). PMID: 30219982 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prevention, Screening & Surveillance
  96. [96]

    Garcia-Prat M, Batlle-Masó L, Parra-Martínez A et al.. “Role of Skewed X-Chromosome Inactivation in Common Variable Immunodeficiency.” Journal of clinical immunology (2024). PMID: 38265673 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  97. [97]

    Gumusburun R, Yıldırım O, Karakoc M et al.. “Malignancy in Adults with Inborn Errors of Immunity: A Retrospective Single-Center Study.” Journal of clinical immunology (2025). PMID: 40993321 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
  98. [98]

    Punj M, Neshat SS, Mateus AYL et al.. “Assessment of Sleep Disorders in Patients with CVID.” Journal of clinical immunology (2024). PMID: 38676767 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
  99. [99]

    Sperlich JM, Grimbacher B, Soetedjo V et al.. “Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders.” Journal of clinical immunology (2022). PMID: 35015197 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
  100. [100]

    Villa A, Milito C, Deiana CM et al.. “High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study.” Journal of clinical immunology (2024). PMID: 38319477 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
  101. [101]

    Puzenat DT, Cheminant M, Dannaoui E et al.. “Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).” The Journal of infectious diseases (2026). PMID: 42378670 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
  102. [102]

    Miranda-Bautista J, Martínez-Lozano H, Di Natale M et al.. “The Prognostic Impact of Enteropathy and Liver Disease in Common Variable Immunodeficiency: A Retrospective Cohort Study.” Clinical and translational gastroenterology (2026). PMID: 41324469 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  103. [103]

    Dogru D, Dogru Y, Atschekzei F et al.. “Reappraisal of IgG subclass deficiencies: a retrospective comparative cohort study.” Frontiers in immunology (2025). PMID: 40313941 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors
  104. [104]

    Cekic S, Metin A, Aytekin C et al.. “The evaluation of malignancies in Turkish primary immunodeficiency patients; a multicenter study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 32060950 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
  105. [105]

    Baris S, Ozen A, Ercan H et al.. “Osteoporosis: an ignored complication of CVID.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2011). PMID: 21645119 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
  106. [106]

    Azizi G, Tavakol M, Yazdani R et al.. “Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33774840 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
  107. [107]

    Zhang J, Cai H, Zhu T et al.. “Clinical, genetic, and functional characterization of novel NFKB1 variants in Chinese patients with primary immunodeficiency.” Clinical and experimental immunology (2026). PMID: 42252100 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks
  108. [108]

    Wenger TA, Collet C, West J et al.. “Rates and Outcomes of Head and Neck Cancer Among Patients With Primary Immunodeficiency Disorders.” Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2026). PMID: 42171009 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
  109. [109]

    Martinez T, Grand Z, Garcia S et al.. “A global perspective on autoimmunity and immunodeficiency: exploring geoepidemiology trends.” Current opinion in immunology (2026). PMID: 41980333 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  110. [110]

    Romberg N, Le Coz C, Glauzy S et al.. “Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses.” The Journal of allergy and clinical immunology (2018). PMID: 29935219 ↗

    L3TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  111. [111]

    Bonilla FA, Barlan I, Chapel H et al.. “International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2015). PMID: 26563668 ↗

    L1OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  112. [112]

    Mayampurath A, Ajith A, Anderson-Smits C et al.. “Early Diagnosis of Primary Immunodeficiency Disease Using Clinical Data and Machine Learning.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36108921 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  113. [113]

    DeVries AS, Harper J, Murray A et al.. “Vaccine-derived poliomyelitis 12 years after infection in Minnesota.” The New England journal of medicine (2011). PMID: 21675890 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  114. [114]

    Lee TK, Gereige JD, Maglione PJ. “State-of-the-art diagnostic evaluation of common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 33716149 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  115. [115]

    Izadi N, Knight V, Strand M et al.. “An enzyme-linked immunospot assay to evaluate Pneumovax response when on intravenous immunoglobulin.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 34391898 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  116. [116]

    Hartono S, Motosue MS, Khan S et al.. “Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 28254202 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  117. [117]

    Kuehn HS, Boisson B, Cunningham-Rundles C et al.. “Loss of B Cells in Patients with Heterozygous Mutations in IKAROS.” The New England journal of medicine (2016). PMID: 26981933 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prevention, Screening & Surveillance
  118. [118]

    Touw CM, van de Ven AA, de Jong PA et al.. “Detection of pulmonary complications in common variable immunodeficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19912551 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  119. [119]

    Reznik EV, Iarovoi MD, Romanova TS et al.. “Prolonged Infections and Inflammatory Diseases in Common Variable Immune Deficiency as a Cause of AA Amyloidosis.” Journal of clinical medicine (2026). PMID: 42278892 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  120. [120]

    Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  121. [121]

    Varenne F, Siegfried-Vergnon A, Lhomme S et al.. “JC Virus-Related Retinopathy.” JAMA ophthalmology (2025). PMID: 40674067 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Acute Management & Anaphylaxis Pathway, Prognosis & Natural History
  122. [122]

    Schwitzguébel AJ, Jandus P, Lacroix JS et al.. “Immunoglobulin deficiency in patients with chronic rhinosinusitis: Systematic review of the literature and meta-analysis.” The Journal of allergy and clinical immunology (2015). PMID: 26329513 ↗

    L1SR_OBSCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  123. [123]

    Jerschow E, De Vos GS, Hudes G et al.. “A case of common variable immunodeficiency syndrome associated with Takayasu arteritis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17304891 ↗

    L4CASE_REPORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  124. [124]

    Renz H. “Advances in in vitro diagnostics in allergy, asthma, and immunology in 2012.” The Journal of allergy and clinical immunology (2013). PMID: 24139605 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance
  125. [125]

    Sperlich JM, Grimbacher B, Workman S et al.. “Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2017). PMID: 28734862 ↗

    L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  126. [126]

    Hurst JR, Verma N, Lowe D et al.. “British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2017). PMID: 28351785 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks
  127. [127]

    Maglione PJ, Ko HM, Tokuyama M et al.. “Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31430592 ↗

    L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
  128. [128]

    Maglione PJ, Overbey JR, Cunningham-Rundles C. “Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.” The journal of allergy and clinical immunology. In practice (2015). PMID: 26372540 ↗

    L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  129. [129]

    Roa-Bautista A, Brown LK, Tadros S et al.. “Clinical Features, Immunological Characteristics, and Treatment Outcomes of Campylobacter spp. Infections in Patients With Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37406804 ↗

    L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
  130. [130]

    Busse PJ, Farzan S, Cunningham-Rundles C. “Pulmonary complications of common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17225714 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  131. [131]

    Deyà-Martínez A, Esteve-Solé A, Vélez-Tirado N et al.. “Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2018). PMID: 29532571 ↗

    L4CASE_REPORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  132. [132]

    Lopes-da-Silva S, Rizzo LV. “Autoimmunity in common variable immunodeficiency.” Journal of clinical immunology (2008). PMID: 18443901 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History, Prevention, Screening & Surveillance
  133. [133]

    Shapiro RS, Wasserman RL, Bonagura V et al.. “Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.” Journal of clinical immunology (2014). PMID: 24477950 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  134. [134]

    Hoernes M, Seger R, Reichenbach J. “Modern management of primary B-cell immunodeficiencies.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2011). PMID: 22122788 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
  135. [135]

    Palmeira P, Costa-Carvalho BT, Arslanian C et al.. “Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19220771 ↗

    L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
  136. [136]

    Stojanovic M, Stojkovic-Lalosevic M, Stankovic S et al.. “Non-invasive assessment of hepatic involvement in common variable immunodeficiency and agammaglobulinemia using enhanced liver fibrosis score and shearwave elastography.” Frontiers in immunology (2026). PMID: 42421971 ↗

    L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
  137. [137]

    Elmoursi A, Charlier C, Cunningham-Rundles C et al.. “Insights into Clinical Challenges and Management of Primary and Secondary Antibody Deficiency in Pregnancy.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42250902 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  138. [138]

    Matson EM, Ware MS, Feng F et al.. “Coexistent alterations of BAFF and B-cell phenotypes in complicated CVID course.” The Journal of allergy and clinical immunology (2026). PMID: 42219089 ↗

    L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  139. [139]

    Smits B, Goldacker S, Seneviratne S et al.. “The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease.” The Journal of allergy and clinical immunology (2022). PMID: 36587851 ↗

    L4RCTCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  140. [140]

    Gardulf A, Abolhassani H, Gustafson R et al.. “Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency.” The Journal of allergy and clinical immunology (2018). PMID: 29678747 ↗

    L4TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  141. [141]

    Chase NM, Verbsky JW, Hintermeyer MK et al.. “Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).” Journal of clinical immunology (2012). PMID: 22930256 ↗

    L4RCTCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  142. [142]

    Bergman P, Wullimann D, Gao Y et al.. “Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2022). PMID: 35290571 ↗

    L2TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification
  143. [143]

    Mandola AB, Sharfe N, Nagdi Z et al.. “Combined immunodeficiency caused by a novel homozygous NFKB1 mutation.” The Journal of allergy and clinical immunology (2020). PMID: 32980423 ↗

    L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
  144. [144]

    Abraham RS, Marshall JM, Kuehn HS et al.. “Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant.” The Journal of allergy and clinical immunology (2020). PMID: 33007327 ↗

    L4CASE_REPORTCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History
  145. [145]

    Materne E, Zhou B, DiGiacomo D et al.. “Renal complications in patients with predominantly antibody deficiency in the United States Immune Deficiency Network (USIDNET).” The Journal of allergy and clinical immunology (2024). PMID: 38555979 ↗

    L2OTHERCited in: Severity, Grading & Risk Stratification
  146. [146]

    Hennig C, Ilginus C, Boztug K et al.. “High-content cytometry and transcriptomic biomarker profiling of human B-cell activation.” The Journal of allergy and clinical immunology (2013). PMID: 24012209 ↗

    L5OTHERCited in: Severity, Grading & Risk Stratification
  147. [147]

    Bintalib HM, van de Ven AAJM, Rojas-Reyes MX et al.. “Clinical Practice Guideline for the diagnosis of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency Disorders (CVID) - an ERS Clinical Research Collaboration.” The European respiratory journal (2026). PMID: 42350065 ↗

    L1GUIDELINECited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
  148. [148]

    Smits BM, Boland SL, Hol ME et al.. “Pulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38182096 ↗

    L2OTHERCited in: Severity, Grading & Risk Stratification
  149. [149]

    Yazdani R, Abolhassani H, Kiaee F et al.. “Comparison of Common Monogenic Defects in a Large Predominantly Antibody Deficiency Cohort.” The journal of allergy and clinical immunology. In practice (2018). PMID: 30240888 ↗

    L2OTHERCited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
  150. [150]

    D'Silva SJ, Patrie J, Noonan E et al.. “Undetectable IgE association with noninfectious complications of common variable immune deficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41390140 ↗

    L2OTHERCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks
  151. [151]

    Boztug H, Hirschmugl T, Holter W et al.. “NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.” Journal of clinical immunology (2016). PMID: 27338827 ↗

    L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
  152. [152]

    Slade CA, McLean C, Scerri T et al.. “Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2.” Journal of clinical immunology (2019). PMID: 30927119 ↗

    L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
  153. [153]

    Karafotias I, Martini H, Lee CV et al.. “CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency.” Journal of clinical immunology (2025). PMID: 41288852 ↗

    L3OTHERCited in: Severity, Grading & Risk Stratification
  154. [154]

    Bergmans B, Fontane Pennock-Janssen L, van Puijenbroek E et al.. “Exploring the Pathogens in Primary Predominantly Antibody Deficiencies of Unknown Genetic Origin.” Journal of clinical immunology (2025). PMID: 41384995 ↗

    L2OTHERCited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
  155. [155]

    Katzenstein TL, Rasmussen LD, Drabe CH et al.. “Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study.” Frontiers in immunology (2022). PMID: 36211430 ↗

    L2COHORTCited in: Severity, Grading & Risk Stratification
  156. [156]

    Danieli MG, Verga JU, Mezzanotte C et al.. “Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.” Frontiers in immunology (2022). PMID: 35111165 ↗

    L4COHORTCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway
  157. [157]

    Russo R, Andolfo I, Lasorsa VA et al.. “The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy.” Genes (2021). PMID: 34201032 ↗

    L3COHORTCited in: Severity, Grading & Risk Stratification
  158. [158]

    van der Heijden J, Geissler J, van Mirre E et al.. “A novel splice variant of FcγRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia.” The Journal of allergy and clinical immunology (2013). PMID: 23545275 ↗

    L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
  159. [159]

    Arora R, Newton TC, Nelson MR. “Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17941286 ↗

    L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy
  160. [160]

    Chinen J, Notarangelo LD, Shearer WT. “Advances in clinical immunology in 2015.” The Journal of allergy and clinical immunology (2016). PMID: 27931534 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  161. [161]

    Chinen J, Badran YR, Geha RS et al.. “Advances in basic and clinical immunology in 2016.” The Journal of allergy and clinical immunology (2017). PMID: 28826774 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  162. [162]

    Bonilla FA, Geha RS. “2. Update on primary immunodeficiency diseases.” The Journal of allergy and clinical immunology (2006). PMID: 16455342 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  163. [163]

    Gathmann B, Mahlaoui N, Gérard L et al.. “Clinical picture and treatment of 2212 patients with common variable immunodeficiency.” The Journal of allergy and clinical immunology (2014). PMID: 24582312 ↗

    L2OTHERCited in: Acute Management & Anaphylaxis Pathway
  164. [164]

    Wehr C, Gennery AR, Lindemans C et al.. “Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency.” The Journal of allergy and clinical immunology (2015). PMID: 25595268 ↗

    L4OTHERCited in: Acute Management & Anaphylaxis Pathway
  165. [165]

    Pulvirenti F, Cinetto F, Milito C et al.. “Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32278865 ↗

    L4OTHERCited in: Acute Management & Anaphylaxis Pathway
  166. [166]

    Zuzolo J, Zulfiqar MF, Spoelhof B et al.. “Functional testing of humoral immunity in the Prevnar 20 era.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 39681261 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
  167. [167]

    Lang-Meli J, Fuchs J, Mathé P et al.. “Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.” Journal of clinical immunology (2021). PMID: 34893946 ↗

    L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
  168. [168]

    Ilkjær FV, Johansen IS, Martin-Iguacel R et al.. “Evaluating Drug Prescription Patterns in Undiagnosed Common Variable Immunodeficiency Patients.” Journal of clinical immunology (2023). PMID: 37833619 ↗

    L3OTHERCited in: Acute Management & Anaphylaxis Pathway
  169. [169]

    Ilkjær FV, Rasmussen LD, Martin-Iguacel R et al.. “How to Identify Common Variable Immunodeficiency Patients Earlier: General Practice Patterns.” Journal of clinical immunology (2019). PMID: 31372799 ↗

    L3OTHERCited in: Acute Management & Anaphylaxis Pathway
  170. [170]

    Lawrence MG, Palacios-Kibler TV, Workman LJ et al.. “Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID).” Journal of clinical immunology (2018). PMID: 29453744 ↗

    L3OTHERCited in: Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
  171. [171]

    Baloh C, Reddy A, Henson M et al.. “30-Year Review of Pediatric- and Adult-Onset CVID: Clinical Correlates and Prognostic Indicators.” Journal of clinical immunology (2019). PMID: 31377970 ↗

    L2REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
  172. [172]

    Cagdas D, Halaçlı SO, Tan Ç et al.. “A Spectrum of Clinical Findings from ALPS to CVID: Several Novel LRBA Defects.” Journal of clinical immunology (2019). PMID: 31432443 ↗

    L4OTHERCited in: Acute Management & Anaphylaxis Pathway
  173. [173]

    Steiner S, Schwarz T, Corman VM et al.. “Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination.” Journal of clinical immunology (2023). PMID: 36932291 ↗

    L4OTHERCited in: Acute Management & Anaphylaxis Pathway
  174. [174]

    Aiello V, Ferrillo M, Marotta N et al.. “Temporomandibular joint arthritis in rheumatic diseases patients: which are the effective rehabilitative approaches for pain relief? A systematic review.” BMC musculoskeletal disorders (2025). PMID: 39966784 ↗

    L1SR_OBSCited in: Acute Management & Anaphylaxis Pathway
  175. [175]

    Budhipramono A, Sharma R, Wysocki CA et al.. “Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting With Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency.” Journal of clinical apheresis (2024). PMID: 39511768 ↗

    L4SR_OBSCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
  176. [176]

    Napiórkowska-Baran K, Biliński J, Pujanek M et al.. “Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy).” Frontiers in cellular and infection microbiology (2024). PMID: 39403201 ↗

    L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
  177. [177]

    Bermingham WH, Canning B, Wilton T et al.. “Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection.” Frontiers in immunology (2023). PMID: 36936936 ↗

    L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
  178. [178]

    Martins B, Miranda J, Pinto MJ et al.. “Common variable immunodeficiency and its inflammatory neurological manifestations: A case report and literature review.” Multiple sclerosis and related disorders (2022). PMID: 35985210 ↗

    L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  179. [179]

    Luterbacher F, Bernard F, Baleydier F et al.. “Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT.” Frontiers in immunology (2021). PMID: 35003091 ↗

    L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
  180. [180]

    Rezaei N, Hedayat M, Aghamohammadi A et al.. “Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.” The Journal of allergy and clinical immunology (2011). PMID: 21514636 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance
  181. [181]

    Mazza JM, Lin SY. “Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review.” International forum of allergy & rhinology (2016). PMID: 27187624 ↗

    L2SR_OBSCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  182. [182]

    Arslan S, Poyraz N, Ucar R et al.. “Magnetic Resonance Imaging May Be a Valuable Radiation-Free Technique for Lung Pathologies in Patients with Primary Immunodeficiency.” Journal of clinical immunology (2015). PMID: 26707785 ↗

    L4OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  183. [183]

    Indinnimeo L, Tancredi G, Barreto M et al.. “Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up.” International journal of immunopathology and pharmacology (2007). PMID: 18179758 ↗

    L1RCTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  184. [184]

    Pietzsch L, Körholz J, Boschann F et al.. “Hyper-IgE and Carcinoma in CADINS Disease.” Frontiers in immunology (2022). PMID: 35651609 ↗

    L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  185. [185]

    Comberiati P, Costagliola G, Carli N et al.. “Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency.” Frontiers in immunology (2019). PMID: 31379880 ↗

    L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  186. [186]

    Suyama K, Kawasaki Y, Abe Y et al.. “Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus.” Pediatric nephrology (Berlin, Germany) (2011). PMID: 22207346 ↗

    L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  187. [187]

    Zdziarski P, Gamian A. “Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency - Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens.” Frontiers in pharmacology (2019). PMID: 30713498 ↗

    L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  188. [188]

    Yuan S, Hu X, Zhao Y et al.. “Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.” Frontiers in immunology (2020). PMID: 33240259 ↗

    L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  189. [189]

    Antachopoulos C, Walsh TJ, Roilides E. “Fungal infections in primary immunodeficiencies.” European journal of pediatrics (2007). PMID: 17551753 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
  190. [190]

    van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM et al.. “Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.” The Journal of allergy and clinical immunology (2022). PMID: 35421449 ↗

    L2RCTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
  191. [191]

    Davé S, Hagan J. “Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 18219840 ↗

    L4CASE_REPORTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  192. [192]

    Morsheimer MM, Rychik J, Forbes L et al.. “Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease.” The journal of allergy and clinical immunology. In practice (2016). PMID: 26897303 ↗

    L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  193. [193]

    van Leeuwen LPM, Grobben M, GeurtsvanKessel CH et al.. “Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.” Journal of clinical immunology (2023). PMID: 37231290 ↗

    L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  194. [194]

    Giardino G, Milito C, Lougaris V et al.. “The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet).” Journal of clinical immunology (2022). PMID: 35445287 ↗

    L4OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
  195. [195]

    Beyls E, Duthoo E, Backers L et al.. “Investigating Chromosomal Radiosensitivity in Inborn Errors of Immunity: Insights from DNA Repair Disorders and Beyond.” Journal of clinical immunology (2025). PMID: 39945898 ↗

    L3OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
  196. [196]

    Lin L, Peng X, Chen L et al.. “Case report: novel NFKB2 variant associated with pediatric eosinophilic granulomatosis with polyangiitis (EGPA) in the COVID-19 pandemic.” Pediatric rheumatology online journal (2025). PMID: 40165201 ↗

    L4CASE_REPORTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
  197. [197]

    Grammatikos A. “Enteropathy in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41935739 ↗

    L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks
  198. [198]

    Gregersen S, Aaløkken TM, Mynarek G et al.. “Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2010). PMID: 20568383 ↗

    L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
  199. [199]

    Nguyen JT, Green A, Wilson MR et al.. “Neurologic Complications of Common Variable Immunodeficiency.” Journal of clinical immunology (2016). PMID: 27704236 ↗

    L4CASE_REPORTCited in: Complications, Comorbidities & Iatrogenic Risks
  200. [200]

    Kralickova P, Kurecova B, Andrys C et al.. “Pregnancy Outcome in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2015). PMID: 26280892 ↗

    L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Special Populations & Pregnancy
  201. [201]

    Zarezadeh Mehrabadi A, Aghamohamadi N, Abolhassani H et al.. “Comprehensive Assessment of Skin Disorders in Patients with Common Variable Immunodeficiency (CVID).” Journal of clinical immunology (2022). PMID: 35084691 ↗

    L4OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
  202. [202]

    Elmoursi A, Zhou B, Ong MS et al.. “A Cross-Sectional Study of Health-Related Quality of Life in Patients with Predominantly Antibody Deficiency.” Journal of clinical immunology (2024). PMID: 39110257 ↗

    L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
  203. [203]

    Cinkavuk E, Akyazi N, Calik E et al.. “An ICF framework analysis of the CVID quality of life questionnaire.” Disability and rehabilitation (2026). PMID: 42080371 ↗

    L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
  204. [204]

    Hayes KM, Boldt K, Schnorr PJ et al.. “Heterozygous NFKB1 variant causes inflammatory dysregulation shaped by broader genetic context in common variable immunodeficiency.” JCI insight (2026). PMID: 41869721 ↗

    L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
  205. [205]

    Delplanque M, Galicier L, Oziol E et al.. “AA Amyloidosis Secondary to Primary Immune Deficiency: About 40 Cases Including 2 New French Cases and a Systematic Literature Review.” The journal of allergy and clinical immunology. In practice (2020). PMID: 33007500 ↗

    L4SR_OBSCited in: Prognosis & Natural History
  206. [206]

    Kuehn HS, Gloude NJ, Dimmock D et al.. “Abnormal SCID Newborn Screening and Spontaneous Recovery Associated with a Novel Haploinsufficiency IKZF1 Mutation.” Journal of clinical immunology (2021). PMID: 33855675 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis & Natural History, Prevention, Screening & Surveillance
  207. [207]

    van Leeuwen LPM, Van Coillie S, Prévot J et al.. “Long-term effects of COVID-19 in patients with primary immunodeficiency: An IPOPI worldwide survey.” The Journal of allergy and clinical immunology (2025). PMID: 40316182 ↗

    L4OTHERCited in: Prognosis & Natural History
  208. [208]

    Verbsky JW, Hintermeyer MK, Simpson PM et al.. “Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2020). PMID: 32745555 ↗

    L4OTHERCited in: Prognosis & Natural History
  209. [209]

    da Silva SP, Resnick E, Lucas M et al.. “Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events.” Journal of clinical immunology (2011). PMID: 21744182 ↗

    L4CASE_REPORTCited in: Prognosis & Natural History
  210. [210]

    Kuehn HS, Nunes-Santos CJ, Rosenzweig SD. “IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.” Journal of clinical immunology (2021). PMID: 33392855 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  211. [211]

    Caka C, Cimen O, Kahyaoğlu P et al.. “Selective IgM deficiency: Follow-up and outcome.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33706406 ↗

    L4OTHERCited in: Prognosis & Natural History, Special Populations & Pregnancy
  212. [212]

    Navale P, Zimmerman O, Wedner J et al.. “Gastrointestinal pathology in Good's syndrome, thinking beyond common variable immunodeficiency: a clinicopathological observation.” Virchows Archiv : an international journal of pathology (2025). PMID: 40140088 ↗

    L4CASE_REPORTCited in: Prognosis & Natural History
  213. [213]

    Roosens W, Staels F, Van Loo S et al.. “Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable immunodeficiency: a case report and literature study.” Frontiers in immunology (2023). PMID: 37795099 ↗

    L4CASE_REPORTCited in: Prognosis & Natural History
  214. [214]

    Almejún MB, Campos BC, Patiño V et al.. “Noninfectious complications in patients with pediatric-onset common variable immunodeficiency correlated with defects in somatic hypermutation but not in class-switch recombination.” The Journal of allergy and clinical immunology (2016). PMID: 27713077 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  215. [215]

    Alsaati N, Penney C, Helbig I et al.. “A predictive model for identification of pediatric individuals with common variable immunodeficiency through electronic medical records.” The Journal of allergy and clinical immunology (2025). PMID: 40058414 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  216. [216]

    van de Ven AA, Compeer EB, Bloem AC et al.. “Defective calcium signaling and disrupted CD20-B-cell receptor dissociation in patients with common variable immunodeficiency disorders.” The Journal of allergy and clinical immunology (2011). PMID: 22130422 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  217. [217]

    Novice T, Kariminia A, Del Bel KL et al.. “A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases.” Journal of clinical immunology (2019). PMID: 31853824 ↗

    L4CASE_REPORTCited in: Special Populations & Pregnancy
  218. [218]

    Freer M, Bhatia R, Preece K et al.. “Dietary intakes and nutritional issues in inborn errors of immunity: a systematic review.” Frontiers in immunology (2024). PMID: 39399505 ↗

    L2SR_OBSCited in: Special Populations & Pregnancy
  219. [219]

    Nijhof LN, van Brussel M, Pots EM et al.. “Severe Fatigue Is Common Among Pediatric Patients with Primary Immunodeficiency and Is Not Related to Disease Activity.” Journal of clinical immunology (2021). PMID: 33728554 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  220. [220]

    Sanchez LA, Maggadottir SM, Pantell MS et al.. “Two Sides of the Same Coin: Pediatric-Onset and Adult-Onset Common Variable Immune Deficiency.” Journal of clinical immunology (2017). PMID: 28755066 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  221. [221]

    Kinoshita H, Durkee-Shock J, Jensen-Wachspress M et al.. “Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.” Journal of clinical immunology (2021). PMID: 33983545 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  222. [222]

    Tanyildiz HG, Dincaslan H, Yavuz G et al.. “Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.” Journal of clinical immunology (2016). PMID: 27492260 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  223. [223]

    Quinti I, Soresina A, Spadaro G et al.. “Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency.” Journal of clinical immunology (2007). PMID: 17510807 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  224. [224]

    Phuong LK, Cheung A, Agrawal R et al.. “Inborn Errors of Immunity in Children With Invasive Pneumococcal Disease: A Multicenter Prospective Study.” The Pediatric infectious disease journal (2023). PMID: 37463351 ↗

    L2COHORTCited in: Special Populations & Pregnancy
  225. [225]

    Adin-Cinar S, Gelmez MY, Akdeniz N et al.. “Functions of NK and iNKT cells in pediatric and adult CVID, ataxia telangiectasia and agammaglobulinemia patients.” Immunology letters (2021). PMID: 34599947 ↗

    L3TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
  226. [226]

    Grześk E, Kołtan S, Dąbrowska A et al.. “Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection.” Frontiers in immunology (2022). PMID: 35990691 ↗

    L4CASE_REPORTCited in: Special Populations & Pregnancy
  227. [227]

    Mokrane L, Tahiat A, Taguemount S et al.. “Improving screening for antibody deficiency using calculated globulin and serum protein electrophoresis.” Frontiers in immunology (2026). PMID: 41929515 ↗

    L4OTHERCited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance
  228. [228]

    Lucas M, Lee M, Lortan J et al.. “Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.” The Journal of allergy and clinical immunology (2010). PMID: 20471071 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  229. [229]

    Mayor PC, Eng KH, Singel KL et al.. “Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry.” The Journal of allergy and clinical immunology (2017). PMID: 28606585 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  230. [230]

    Green PHR, Paski S, Ko CW et al.. “AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review.” Gastroenterology (2022). PMID: 36137844 ↗

    L1GUIDELINECited in: Prevention, Screening & Surveillance
  231. [231]

    Israeli S, Golden A, Atalig M et al.. “A Novel Point-of-Care Rapid Diagnostic Test for Screening Individuals for Antibody Deficiencies.” Journal of clinical immunology (2021). PMID: 34839430 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  232. [232]

    Kermode W, De Santis D, Truong L et al.. “A Novel Targeted Amplicon Next-Generation Sequencing Gene Panel for the Diagnosis of Common Variable Immunodeficiency Has a High Diagnostic Yield: Results from the Perth CVID Cohort Study.” The Journal of molecular diagnostics : JMD (2022). PMID: 35570134 ↗

    L4COHORTCited in: Prevention, Screening & Surveillance
  233. [233]

    Nassereddin AT, Zayed Y, King RB et al.. “A 28-Year-Old Woman With Nail Discoloration, Recurrent Bronchitis, and Left-Sided Facial Swelling.” Chest (2023). PMID: 37945195 ↗

    L4CASE_REPORTCited in: Prevention, Screening & Surveillance
  234. [234]

    Camacho-Ordonez N, Hirsch A, Campos L et al.. “Do CVID patients on SCIG have more autoimmune (thrombo)cytopenic events than CVID patients on IVIG?” Frontiers in immunology (2025). PMID: 41394859 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  235. [235]

    Alba-Cano T, Alonso R, Balastegui-Martín H et al.. “Impact of CMV latency on T-cell responses to COVID-19 vaccination among predominantly antibody-deficient patients.” Frontiers in immunology (2025). PMID: 41098714 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…